Allogene Therapeutics, Inc.(ALLO)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Allogene Therapeutics, Inc. (ALLO) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores ALLO at 33.9/100 on a 32-signal composite quality model, placing it at rank #2,371 of 2,962 stocks — the bottom half of the AI-ranked universe. ALLO scores in the top quartile across revenue growth (99.3), institutional flow (95.0). Areas of concern include profitability (1.5) and free cash flow (1.5), which score below median versus the broader universe. Shareholder dilution risk is elevated at 0.6/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Allogene Therapeutics, Inc. reports quarterly revenue of $4.6M, net income of $-42.7M, free cash flow of $-32.1M. Top institutional holders of ALLO by reported 13-F value include BlackRock, PFIZER, Frazier Life Sciences Management, L.P., based on the most recent SEC filings. ALLO trades on the Nasdaq exchange and files with the SEC under CIK 1737287. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate ALLO daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Allogene Therapeutics, Inc. directly from SEC EDGAR.